In the preclinical studies, PBI-1737 displayed significant antitumor activity in human prostate cancer both in vitro and in vivo. The in vivo study demonstrated a significant reduction in tumor volume both alone (p < 0.05) and in combination with cyclophosphamide (p < 0.01). The preclinical study on PBI-0110 in combination with gemcitabine in intradermal and orthotopic pancreatic cancer showed that PBI-0110 alone significantly inhibited pancreatic tumor growth in mouse models by as much as 58% (p < 0.05) after 44 days. The study also demonstrated a dose dependent inhibition of tumor growth, with the 400mg/kg dose being the most effective, inhibiting growth by nearly 40% after 25 days (p < 0.05). The combination therapy of 100mg/kg PBI-0110 and gemcitabine also demonstrated similar efficacy. Finally, the study demonstrated increased survival in mice that received the combination therapy of PBI-0110 200mg/kg and gemcitabine. The preclinical study on PBI-1308 demonstrated a reduction of inflammation and cancer cell proliferation through inhibition of NF-kappaB in prostate cancer and inhibition of TNF-alpha, and inflammatory cytokine. Pierre Laurin, president and CEO of ProMetic Life Sciences, said: "We are assembling a broad pipeline of promising candidates for various cancers, which augments PBI-1402, our lead compound which has shown compelling human data for the treatment of chemotherapy-induced anemia."